In my role as an EIC, I am proud and happy to announce that *Degenerative Neurological and Neuromuscular Disease* is now included in the PubMed database. This is a big step forward for the development of this journal and will hopefully generate more submissions and exposure for our authors.

*Degenerative Neurological and Neuromuscular Disease* is an open access journal that provides authors the ability to publish novel papers that can then be read by anyone with access to the Internet, and therefore increasing exposure and encouraging scientific discussions in the important field of chronic neurodegenerative and neuromuscular disorders.

From pharmaceutical advances, such as riluzole in the extension of median survival times in patients with amyotrophic lateral sclerosis,[@b1-dnnd-9-001] to updated perspectives on biomarkers of Duchenne muscular dystrophy,[@b2-dnnd-9-001] research published in *Degenerative Neurological and Neuromuscular Disease* has made a substantial difference in its field. Key papers of interest include "Randomized control trial evaluation of a modified Paleolithic dietary intervention in the treatment of relapsing-remitting multiple sclerosis: a pilot study"[@b3-dnnd-9-001] by Irish et al, which has the highest Altmetric score of the journal.

This journal welcomes the submission of reviews, case reports, study reports, novel post hoc analyses, and original research on all aspects of degenerative neurological and neuromuscular diseases, including the identification of therapeutic targets, pathophysiology, biomarker and cellular research, epidemiology, and the optimal use of preventative and integrated treatment interventions. All papers submitted to the journal undergo a rigorous and fast peer review process. I hope this journal's approach will find further growing interest in the scientific community, as it continues to achieve its aim of increasing exposure of discussions and insights in the field.

I would like to thank everyone who has helped the journal achieve in the years since its launch in 2011, and we welcome your submissions.
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